Wegovy (semaglutide), a GLP-1 receptor agonist approved in August 2025 for adults with moderate-to-advanced fibrosis, provides benefits partly through weight loss, but its mechanism in MASH remains incompletely understood [56]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.